GT Biopharma Reports Third Quarter 2026 Financial Results
Globe Newswire•16/11/2026•07:00 ET
1
Key Highlights
- ➤Cash balance $10 million, expected to fund operations into Q3 2027
- ➤FDA cleared new GTB-5550 IND for multiple myeloma; trial awaits grant funding
- ➤GTB-3650 Phase 1 Cohort 4 completed; Cohort 5 enrollment underway
- ➤GTB-5550 solid-tumor Phase 1 Cohort 3 enrollment is in progress
- ➤Q3 net loss $3.5 million versus $8.3 million net income in Q3 2025
Expert Statements
Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma
“This quarter we broadened the potential reach of GTB-5550 with FDA clearance of a new IND in multiple myeloma, while continuing to enroll patients in both of our ongoing Phase 1 trials”
Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma
“This expansion reflects the versatility of our TriKE(®) platform, and our growing use of AI-based tools is helping us identify additional development candidates for 2027.”
Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma
“With cash runway into Q3 2027, we are well positioned and look forward to providing updates on both Phase 1 programs in the fourth quarter.”
Phase 1 trial evaluating GTB-3650 TriKE(®) remains ongoing, with an update anticipated in Q4 2026
Phase 1 basket trial evaluating GTB-5550 TriKE(® )in multiple solid tumor types known to express B7-H3 remains ongoing, with an update anticipated in Q4 2026
Get started
Create a free account to read the full story.
